JP2021506246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021506246A5 JP2021506246A5 JP2020531982A JP2020531982A JP2021506246A5 JP 2021506246 A5 JP2021506246 A5 JP 2021506246A5 JP 2020531982 A JP2020531982 A JP 2020531982A JP 2020531982 A JP2020531982 A JP 2020531982A JP 2021506246 A5 JP2021506246 A5 JP 2021506246A5
- Authority
- JP
- Japan
- Prior art keywords
- immunostimulatory oligonucleotide
- linker
- cholesteryl
- oligonucleotide according
- immunostimulatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003308 immunostimulating Effects 0.000 claims 27
- 229920000272 Oligonucleotide Polymers 0.000 claims 24
- 125000005647 linker group Chemical group 0.000 claims 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 5
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims 4
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims 4
- 230000027455 binding Effects 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- XXMIOPMDWAUFGU-UHFFFAOYSA-N 1,6-Hexanediol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 claims 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 1
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 229960005486 vaccines Drugs 0.000 claims 1
Claims (24)
- 少なくとも1つのCpGモチーフ及び3’コレステリル部分を含む免疫刺激性オリゴヌクレオチド。
- 免疫刺激性オリゴヌクレオチドのヌクレオチド間にホスホジエステル結合またはホスホロチオエート結合を含む、請求項1記載の免疫刺激性オリゴヌクレオチド。
- コレステリル部分がリンカーを介して免疫刺激オリゴヌクレオチドの3’末端ヌクレオチドに共有結合されている、請求項1または2に記載の免疫刺激オリゴヌクレオチド。
- 多数のチミンヌクレオチドを含む3’末端配列を含む、請求項1〜3のいずれか一項に記載の免疫刺激性オリゴヌクレオチド。
- 免疫刺激性オリゴヌクレオチドが、配列番号2、3、4、5、6又は8を含む、請求項1〜4のいずれか一項に記載の免疫刺激性オリゴヌクレオチド。
- 免疫刺激オリゴヌクレオチドの3’末端配列が多数のグアニンヌクレオチドを含む、請求項4に記載の免疫刺激オリゴヌクレオチド。
- 免疫刺激性オリゴヌクレオチドが配列番号7を含む、請求項6に記載の免疫刺激性オリゴヌクレオチド。
- 免疫刺激性オリゴヌクレオチドが(TCG)nを含み、ここでnは3と10の間である、請求項1〜4のいずれか一項に記載の免疫刺激性オリゴヌクレオチド。
- リンカーが炭素鎖を含む、請求項3〜8のいずれか一項に記載の免疫刺激性オリゴヌクレオチド。
- リンカーが反復化学単位を含む、請求項3〜9のいずれか一項に記載の免疫刺激性オリゴヌクレオチド。
- 反復化学単位が、2回から12回の間で反復される、請求項11に記載の免疫刺激性オリゴヌクレオチド。
- 反復化学単位が、エチレングリコールである、請求項11に記載の免疫刺激性オリゴヌクレオチド。
- リンカーが、ヘキサメチレングリコールを含む、請求項11〜13のいずれか一項に記載の免疫刺激性オリゴヌクレオチド。
- コレステリル部分が、リンカーと共有結合してコレステリル−リンカー部分を形成する、請求項11〜14のいずれか一項に記載の免疫刺激性オリゴヌクレオチド。
- 請求項1〜16のいずれか一項に記載の免疫刺激性オリゴヌクレオチドを含む免疫刺激性組成物。
- 感染性疾患を予防又は治療するためのワクチンをさらに含む、請求項17に記載の免疫刺激性組成物。
- ベクターをさらに含む、請求項17又は18に記載の免疫刺激性組成物。
- 薬学的に許容される担体をさらに含む、請求項17〜19のいずれか一項に記載の免疫刺激性組成物。
- リンカーを介してコレステリル部分をTLR9リガンドの3’末端に付着させることを含む、TLR9リガンドの免疫原性を増強する方法であって、ここで、
TLR9リガンドは、少なくとも1つのCpGモチーフを有するオリゴヌクレオチドである、方法。 - コレステリル部分が、リンカーに共有結合してコレステリル−リンカー部分を形成する、請求項21に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023128316A JP2023153970A (ja) | 2017-12-15 | 2023-08-07 | 免疫刺激性オリゴヌクレオチド |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17207746 | 2017-12-15 | ||
EP17207740.6 | 2017-12-15 | ||
EP17207746.3 | 2017-12-15 | ||
EP17207740 | 2017-12-15 | ||
EP17207750 | 2017-12-15 | ||
EP17207750.5 | 2017-12-15 | ||
PCT/EP2018/084019 WO2019115402A1 (en) | 2017-12-15 | 2018-12-07 | Immunostimulatory oligonucleotides |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023128316A Division JP2023153970A (ja) | 2017-12-15 | 2023-08-07 | 免疫刺激性オリゴヌクレオチド |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021506246A JP2021506246A (ja) | 2021-02-22 |
JP2021506246A5 true JP2021506246A5 (ja) | 2022-01-11 |
Family
ID=66818991
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020531982A Pending JP2021506246A (ja) | 2017-12-15 | 2018-12-07 | 免疫刺激性オリゴヌクレオチド |
JP2020531988A Active JP7458977B2 (ja) | 2017-12-15 | 2018-12-07 | 免疫刺激性組成物 |
JP2020531972A Active JP7273040B2 (ja) | 2017-12-15 | 2018-12-07 | 免疫刺激性オリゴヌクレオチド |
JP2023128316A Pending JP2023153970A (ja) | 2017-12-15 | 2023-08-07 | 免疫刺激性オリゴヌクレオチド |
JP2023134080A Pending JP2023156485A (ja) | 2017-12-15 | 2023-08-21 | 免疫刺激性組成物 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020531988A Active JP7458977B2 (ja) | 2017-12-15 | 2018-12-07 | 免疫刺激性組成物 |
JP2020531972A Active JP7273040B2 (ja) | 2017-12-15 | 2018-12-07 | 免疫刺激性オリゴヌクレオチド |
JP2023128316A Pending JP2023153970A (ja) | 2017-12-15 | 2023-08-07 | 免疫刺激性オリゴヌクレオチド |
JP2023134080A Pending JP2023156485A (ja) | 2017-12-15 | 2023-08-21 | 免疫刺激性組成物 |
Country Status (21)
Country | Link |
---|---|
US (6) | US20210062192A1 (ja) |
EP (3) | EP3694549A1 (ja) |
JP (5) | JP2021506246A (ja) |
KR (3) | KR20200099556A (ja) |
CN (3) | CN111447949A (ja) |
AU (3) | AU2018385257A1 (ja) |
BR (3) | BR112020011838A2 (ja) |
CA (3) | CA3085575A1 (ja) |
CL (3) | CL2020001562A1 (ja) |
CO (3) | CO2020007120A2 (ja) |
CR (1) | CR20200260A (ja) |
DO (3) | DOP2020000107A (ja) |
IL (3) | IL274975A (ja) |
MX (3) | MX2020006246A (ja) |
PE (2) | PE20210635A1 (ja) |
PH (3) | PH12020550906A1 (ja) |
SG (3) | SG11202004773SA (ja) |
TW (3) | TWI821224B (ja) |
UY (3) | UY38016A (ja) |
WO (3) | WO2019115386A1 (ja) |
ZA (1) | ZA202004317B (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3993834A1 (en) | 2019-07-05 | 2022-05-11 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
CN113493790A (zh) * | 2020-04-01 | 2021-10-12 | 南京华普生物技术股份有限公司 | 具有免疫调节功能的CpG ODN及其应用 |
EP3892260A1 (en) * | 2020-04-10 | 2021-10-13 | Bayer Animal Health GmbH | Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids |
WO2022032191A1 (en) | 2020-08-07 | 2022-02-10 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
CN112159814B (zh) * | 2020-10-29 | 2023-05-16 | 中国农业科学院兰州兽医研究所 | 一种CpG寡聚脱氧核苷酸及制备与其用途 |
CN113797329A (zh) * | 2021-10-19 | 2021-12-17 | 启锰生物科技(江苏)有限公司 | 一种二价锰佐剂和CpG佐剂的疫苗佐剂组合物及其制作方法 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5719028A (en) * | 1992-12-07 | 1998-02-17 | Third Wave Technologies Inc. | Cleavase fragment length polymorphism |
ATE420171T1 (de) | 1994-07-15 | 2009-01-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
DK1221955T3 (da) * | 1999-09-25 | 2006-01-30 | Univ Iowa Res Found | Immunstimulerende nukleinsyre |
CA2386019C (en) * | 1999-09-27 | 2011-06-21 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
KR100359753B1 (ko) | 1999-12-21 | 2002-11-09 | 주식회사 제넥신 | 면역조절능력 및 안전성이 증가되고 dG 연속서열이결합된 포스포다이에스터 CpG올리고데옥시뉴클레오티드 변형체 |
AR040996A1 (es) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
EP2371834B1 (en) * | 2003-06-11 | 2016-02-17 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
CA2536139A1 (en) * | 2003-09-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
KR101107818B1 (ko) * | 2003-10-30 | 2012-01-31 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 향상된 면역자극 효능을 가진 c-부류 올리고뉴클레오티드유사체 |
AU2004291277A1 (en) * | 2003-11-05 | 2005-06-02 | Intercell Ag | Compositions comprising melittin-derved peptides and methods for the potentiation of immune responses against target antigens |
KR100558851B1 (ko) * | 2004-01-08 | 2006-03-10 | 학교법인연세대학교 | 면역조절능력이 증가된 CpG 올리고데옥시뉴클레오티드변형체 |
DE602005012948D1 (de) * | 2004-05-06 | 2009-04-09 | Us Gov Health & Human Serv | Verfahren und zusammensetzungen zur behandlung von uveitis |
US20080009455A9 (en) * | 2005-02-24 | 2008-01-10 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
EP1764108A1 (en) * | 2005-09-14 | 2007-03-21 | Gunther Hartmann | Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides |
JP5473336B2 (ja) * | 2006-02-15 | 2014-04-16 | アディウタイド・ファーマスーティカルズ・ゲーエムベーハー | オリゴヌクレオチドの処方に関する組成物および方法 |
CN100418583C (zh) | 2006-02-21 | 2008-09-17 | 朱鸿飞 | 预防和治疗乳腺炎的药物组合物 |
US20080124366A1 (en) * | 2006-08-06 | 2008-05-29 | Ohlfest John R | Methods and Compositions for Treating Tumors |
CN101240271B (zh) * | 2006-08-28 | 2012-08-29 | 长春华普生物技术有限公司 | Toll样受体调节性寡核苷酸及其用途 |
MX2009003398A (es) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada. |
RU2435851C2 (ru) * | 2007-08-13 | 2011-12-10 | Коули Фармасьютикал ГмбХ | Мотивы последовательности рнк в контексте определенных межнуклеотидных связей, индуцирующие специфические иммуномодулирующие профили |
WO2010129672A1 (en) | 2009-05-05 | 2010-11-11 | Miragen Therapeutics | Lipophilic polynucleotide conjugates |
RU2570732C9 (ru) * | 2009-05-14 | 2016-09-10 | Байер Интеллектуэль Проперти Гмбх | Усиленный иммунный ответ у видов птиц |
EP2575878B1 (en) * | 2010-05-28 | 2018-06-13 | Zoetis Belgium S.A. | Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules |
JP6058550B2 (ja) | 2010-12-22 | 2017-01-11 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | ウシの種における免疫応答の増強 |
EP2471926A3 (en) | 2010-12-30 | 2012-07-11 | Intervet International BV | Immunostimulatory oligodeoxynucleotides |
MX2013013801A (es) * | 2011-05-26 | 2013-12-16 | Intervet Int Bv | Oligodesoxinucleotidos inmunoestimuladores. |
RU2587633C2 (ru) * | 2011-05-26 | 2016-06-20 | Интервет Интернэшнл Б.В. | Иммуностимулирующие олигодезоксинуклеотиды |
US9107904B2 (en) * | 2012-04-05 | 2015-08-18 | Massachusetts Institute Of Technology | Immunostimulatory compositions and methods of use thereof |
AR091569A1 (es) * | 2012-06-28 | 2015-02-11 | Intervet Int Bv | Receptores de tipo toll |
AU2013347838A1 (en) * | 2012-11-26 | 2015-06-11 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarker compositions and methods |
CN105164261B (zh) | 2013-05-01 | 2022-03-18 | 莱古路斯治疗法股份有限公司 | 用于增强的细胞摄取的化合物和方法 |
WO2015010070A1 (en) * | 2013-07-19 | 2015-01-22 | National Health Research Institutes | Cpg-oligodeoxynucleotide, immunogenic composition comprising the same, and methods for preparing the composition and stimulating immune response thereby |
AR097029A1 (es) | 2013-07-26 | 2016-02-17 | Intervet Int Bv | Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune |
GB2517700A (en) * | 2013-08-27 | 2015-03-04 | Lgc Ltd | Oligonucleotides comprising a secondary structure and uses thereof |
EP3110940A1 (en) * | 2014-02-28 | 2017-01-04 | Bayer Animal Health GmbH | Immunostimulatory plasmids |
WO2017139570A1 (en) | 2016-02-12 | 2017-08-17 | Massachusetts Intitute Of Technology | Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne |
-
2018
- 2018-12-07 AU AU2018385257A patent/AU2018385257A1/en active Pending
- 2018-12-07 BR BR112020011838-9A patent/BR112020011838A2/pt unknown
- 2018-12-07 AU AU2018385256A patent/AU2018385256A1/en active Pending
- 2018-12-07 BR BR112020011845-1A patent/BR112020011845A2/pt unknown
- 2018-12-07 US US16/771,789 patent/US20210062192A1/en not_active Abandoned
- 2018-12-07 JP JP2020531982A patent/JP2021506246A/ja active Pending
- 2018-12-07 CA CA3085575A patent/CA3085575A1/en active Pending
- 2018-12-07 MX MX2020006246A patent/MX2020006246A/es unknown
- 2018-12-07 KR KR1020207020350A patent/KR20200099556A/ko not_active Application Discontinuation
- 2018-12-07 US US16/772,046 patent/US11542507B2/en active Active
- 2018-12-07 AU AU2018382419A patent/AU2018382419A1/en active Pending
- 2018-12-07 JP JP2020531988A patent/JP7458977B2/ja active Active
- 2018-12-07 CN CN201880080814.7A patent/CN111447949A/zh active Pending
- 2018-12-07 SG SG11202004773SA patent/SG11202004773SA/en unknown
- 2018-12-07 CN CN201880089469.3A patent/CN111801419A/zh active Pending
- 2018-12-07 KR KR1020207020351A patent/KR20200098638A/ko not_active Application Discontinuation
- 2018-12-07 EP EP18829227.0A patent/EP3694549A1/en active Pending
- 2018-12-07 PE PE2020000765A patent/PE20210635A1/es unknown
- 2018-12-07 WO PCT/EP2018/083958 patent/WO2019115386A1/en unknown
- 2018-12-07 CA CA3085657A patent/CA3085657A1/en active Pending
- 2018-12-07 BR BR112020011815-0A patent/BR112020011815A2/pt unknown
- 2018-12-07 PE PE2020000766A patent/PE20210636A1/es unknown
- 2018-12-07 SG SG11202004471RA patent/SG11202004471RA/en unknown
- 2018-12-07 MX MX2020006243A patent/MX2020006243A/es unknown
- 2018-12-07 CR CR20200260A patent/CR20200260A/es unknown
- 2018-12-07 MX MX2020006244A patent/MX2020006244A/es unknown
- 2018-12-07 EP EP18829225.4A patent/EP3700564A1/en active Pending
- 2018-12-07 CA CA3085661A patent/CA3085661A1/en active Pending
- 2018-12-07 KR KR1020207020349A patent/KR20200098637A/ko not_active Application Discontinuation
- 2018-12-07 US US16/772,541 patent/US11932857B2/en active Active
- 2018-12-07 EP EP18811581.0A patent/EP3701032A1/en active Pending
- 2018-12-07 SG SG11202004952UA patent/SG11202004952UA/en unknown
- 2018-12-07 JP JP2020531972A patent/JP7273040B2/ja active Active
- 2018-12-07 WO PCT/EP2018/083956 patent/WO2019115385A1/en unknown
- 2018-12-07 CN CN201880089491.8A patent/CN111801116A/zh active Pending
- 2018-12-07 WO PCT/EP2018/084019 patent/WO2019115402A1/en unknown
- 2018-12-13 TW TW107144947A patent/TWI821224B/zh active
- 2018-12-13 TW TW107144948A patent/TW201936924A/zh unknown
- 2018-12-13 TW TW107144946A patent/TW201940192A/zh unknown
- 2018-12-14 UY UY0001038016A patent/UY38016A/es not_active Application Discontinuation
- 2018-12-14 UY UY0001038014A patent/UY38014A/es not_active Application Discontinuation
- 2018-12-14 UY UY0001038015A patent/UY38015A/es not_active Application Discontinuation
-
2020
- 2020-05-27 IL IL274975A patent/IL274975A/en unknown
- 2020-06-03 IL IL275086A patent/IL275086A/en unknown
- 2020-06-08 IL IL275217A patent/IL275217A/en unknown
- 2020-06-10 DO DO2020000107A patent/DOP2020000107A/es unknown
- 2020-06-10 DO DO2020000113A patent/DOP2020000113A/es unknown
- 2020-06-10 DO DO2020000106A patent/DOP2020000106A/es unknown
- 2020-06-11 CO CONC2020/0007120A patent/CO2020007120A2/es unknown
- 2020-06-11 CL CL2020001562A patent/CL2020001562A1/es unknown
- 2020-06-11 CL CL2020001561A patent/CL2020001561A1/es unknown
- 2020-06-11 CO CONC2020/0007102A patent/CO2020007102A2/es unknown
- 2020-06-11 CO CONC2020/0007100A patent/CO2020007100A2/es unknown
- 2020-06-11 CL CL2020001560A patent/CL2020001560A1/es unknown
- 2020-06-15 PH PH12020550906A patent/PH12020550906A1/en unknown
- 2020-06-15 PH PH12020550903A patent/PH12020550903A1/en unknown
- 2020-06-15 PH PH12020550904A patent/PH12020550904A1/en unknown
- 2020-07-14 ZA ZA2020/04317A patent/ZA202004317B/en unknown
-
2022
- 2022-08-08 US US17/883,031 patent/US20230174990A1/en active Pending
- 2022-11-18 US US18/057,053 patent/US20230332162A1/en active Pending
-
2023
- 2023-08-07 US US18/366,306 patent/US20240076681A1/en active Pending
- 2023-08-07 JP JP2023128316A patent/JP2023153970A/ja active Pending
- 2023-08-21 JP JP2023134080A patent/JP2023156485A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021506246A5 (ja) | ||
JP2023073507A5 (ja) | ||
JP2020022483A5 (ja) | ||
JP2019062913A5 (ja) | ||
JP2023113843A5 (ja) | ||
JP2018507711A5 (ja) | ||
JP2018183178A5 (ja) | ||
JP2019503394A5 (ja) | ||
RU2013114396A (ru) | Антисмысловые нуклеиновые кислоты | |
JP2006515277A5 (ja) | ||
JP2016502858A5 (ja) | ||
JP2018512110A5 (ja) | ||
JP2017079759A5 (ja) | ||
RU2009142211A (ru) | Класс олигонуклеотидов с иммуностимулирующей активностью | |
JP2015514418A5 (ja) | ||
JP2018520685A5 (ja) | ||
JP2013510561A5 (ja) | ||
JP2006502694A5 (ja) | ||
JP2010528041A5 (ja) | ||
JP2007504830A5 (ja) | ||
KR930701466A (ko) | 안티센스 올리고뉴클레오티드에 의한 a형 인플루엔자 바이러스, 안 아아보 스트레인(ann arbor strain)h2n2의 억제 | |
JP2019534009A5 (ja) | ||
JP2008544983A5 (ja) | ||
JP2005525991A5 (ja) | ||
RU2020115761A (ru) | МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В |